Research Collaboration and Exclusive License Agreement - Additional Information (Detail) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022 USD ($)	Jun. 30, 2021 USD ($)	Jun. 30, 2022 USD ($) Target	Jun. 30, 2021 USD ($)	Dec. 31, 2021 USD ($)
Research And Development Arrangement Contract To Perform For Others [Line Items]
Deferred revenue current	$ 5,371		$ 5,371		$ 5,163
Accounts receivable outstanding	0		$ 0		0
Merck Agreement
Research And Development Arrangement Contract To Perform For Others [Line Items]
Collaborative arrangement effective date			Dec. 15, 2020
Number of collaboration targets | Target			2
Non-refundable and non-creditable upfront fee			$ 8,000
Payable upon selection of second collaboration target	8,000		8,000
Milestone payments			285,000
Revenue recognized	2,400	$ 500	4,000	$ 900
Deferred revenue	$ 10,700		10,700
Deferred revenue current					$ 5,400
Merck Agreement | Maximum
Research And Development Arrangement Contract To Perform For Others [Line Items]
Milestone payments per collaboration target			142,500
Milestone payments upon successful completion of certain commercial milestones			350,000
Merck Agreement First Collaboration Target
Research And Development Arrangement Contract To Perform For Others [Line Items]
Non-refundable and non-creditable upfront fee			8,000
Transaction price			11,400
Reimbursable research program funding for first collaboration target			3,400
Aggregate transaction price allocated to unsatisfied performance obligation			1,100
Merck Agreement Second Collaboration Target
Research And Development Arrangement Contract To Perform For Others [Line Items]
Non refundable and non-creditable target payment received			$ 8,000